(REGN) Regeneron Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(REGN) Regeneron Pharmaceuticals, Inc. Bundle
Download Your Competitive Advantage
This Regeneron Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Dupixent $14B plus 7 indications
Dupixent is Regeneron Pharmaceuticals, Inc.’s biggest growth engine, with 2025 sales above $14B and 7 approved indications across type 2 inflammation. Its broad label keeps expanding, and the brand holds strong share in asthma, atopic dermatitis, COPD, and CRSwNP. That mix of fast growth, scale, and market leadership fits classic Star status in the BCG Matrix.
Dupixent COPD first U.S. biologic 2024
Dupixent’s 2024 U.S. COPD approval opened a huge new market, with COPD affecting about 16 million Americans and millions more undiagnosed. The launch pushed Dupixent beyond dermatology and asthma, supporting its 2024 global sales of about $13.6 billion. Even low share in COPD can add big revenue, so it stays a Star for Regeneron Pharmaceuticals, Inc.
Dupixent atopic dermatitis category leader
Dupixent is Regeneron Pharmaceuticals, Inc.'s atopic dermatitis Star: the U.S. and global AD market is still large, and Dupixent reached $13.0 billion in 2024 sales, showing scale and demand. Broad adult and pediatric use, plus strong physician adoption, keeps share high and supports continued growth. That mix of high share and expansion is classic Star behavior.
Dupixent asthma broad adult and pediatric use
Dupixent is a Star because asthma is a long-duration market and the drug now serves broad adult and pediatric groups, including children as young as 6 months for certain asthma types. Regeneron said Dupixent remained a top growth engine in 2025, with global sales above the $14 billion scale set in 2024, and the brand keeps taking share from inhaled steroids and older biologics.
- Broad age reach supports repeat use
- Chronic asthma means long treatment cycles
- Switching from older therapy keeps growing
ARCALYST 2 orphan indications CAPS and recurrent pericarditis
ARCALYST has moved from a narrow CAPS orphan drug into a larger specialty franchise, and recurrent pericarditis has widened the addressable pool well beyond the ultra-rare CAPS base. The drug is FDA-approved for CAPS and recurrent pericarditis, and Regeneron has said the recurrent pericarditis launch expanded use into a much bigger market.
That is Star-like: the market is still growing, and ARCALYST has a strong niche position with clear clinical differentiation. CAPS remains tiny, but recurrent pericarditis adds far more patients, so the brand can keep scaling without needing a broad primary-care push.
- CAPS is ultra-rare.
- Recurrent pericarditis expands reach.
- ARCALYST has niche share strength.
- Fit: Star in BCG matrix.
Dupixent Powers Regeneron’s Growth With $14B+ Sales
Dupixent is Regeneron Pharmaceuticals, Inc.’s clear Star: 2025 sales topped $14 billion, up from $13.6 billion in 2024, and the brand now spans 7 approved indications. Its growth in asthma, atopic dermatitis, COPD, and CRSwNP shows high share plus fast expansion.
| Asset | 2025 Sales | BCG fit |
|---|---|---|
| Dupixent | Above $14B | Star |
What is included in the product
Detailed Word Document
Regeneron’s BCG Matrix maps its portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for smart invest/hold/divest calls.
Editable Excel File
One-page Regeneron BCG Matrix to quickly spot pain-point relievers and growth bets.
Reference Sources
Regeneron Pharmaceuticals, Inc. Reference Sources provide a credible audit trail that strengthens trust and supports faster, better decisions.
Cash Cows
Eylea 2 mg wet AMD multibillion revenue base
Eylea 2 mg still anchors Regeneron Pharmaceuticals, Inc.'s wet AMD franchise, which remains a mature but cash-rich legacy market. Even as newer anti-VEGF options and biosimilars pressure growth, the 2 mg brand still drives billions in annual sales and supports high operating cash flow. That steady, lower-growth, high-margin profile is classic Cash Cow behavior.
Eylea 2 mg diabetic macular edema
DME is a large, established retinal market, and Eylea 2 mg still holds a strong share in a mature segment. Regeneron Pharmaceuticals, Inc. said Eylea franchise sales were still in the multi-billion-dollar range in its latest filings, but growth has slowed as the market matures and newer dosing options expand. That fits Cash Cow economics: steady cash flow, lower launch support, and limited incremental spend.
Eylea 2 mg retinal vein occlusion
Eylea 2 mg for retinal vein occlusion sits in a mature market with stable prescribing and strong brand recognition. Regeneron generated $5.45 billion in Eylea U.S. net sales in 2024, showing the franchise still throws off major cash even as growth slows. That makes RVO a classic Cash Cow: dependable income, not rapid expansion.
Eylea ex-U.S. Bayer collaboration
Outside the U.S., Eylea is a mature, low-promo franchise run through Bayer’s long-set collaboration with Regeneron Pharmaceuticals, Inc., with Regeneron typically sharing 50% of profits and losses. Strong brand awareness and Bayer’s established sales force keep demand steady, so this line keeps turning cash with limited fresh spending.
Eylea’s ex-U.S. role fits Cash Cow status because the market is already built, physician adoption is entrenched, and the product has been commercialized for years since its 2012 EU launch. Even as Regeneron pushes newer drugs, this collaboration still provides recurring economics and stable contribution.
- 50% profit-share economics
- Established ex-U.S. sales channel
- Low promotion needs
- Mature, high-recognition brand
Eylea legacy franchise 2024 cash generation
Eylea remains a Cash Cow for Regeneron Pharmaceuticals, Inc.: the legacy franchise still throws off strong cash even as biosimilar pressure slows growth. In 2024, the business stayed highly profitable and helped fund a large share of Regeneron Pharmaceuticals, Inc. R&D spend, which was about $5.9 billion. Mature share, strong margins, and repeat demand keep it a key funding source.
- Eylea still funds Regeneron Pharmaceuticals, Inc. R&D.
- Growth slowed under biosimilar pressure.
- High margins fit a Cash Cow profile.
Eylea 2 mg Powers Regeneron’s Cash Flow Engine
Eylea 2 mg is Regeneron Pharmaceuticals, Inc.'s main Cash Cow: a mature retinal franchise with strong repeat demand, high margins, and lower growth needs. In 2024, Regeneron Pharmaceuticals, Inc. reported $5.45 billion in U.S. Eylea net sales, while R&D was about $5.9 billion, showing how the franchise helps fund innovation.
| Cash Cow | Key data |
|---|---|
| Eylea 2 mg | $5.45B U.S. net sales; mature market; high cash flow |
Preview Before You Purchase
Regeneron Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact Regeneron Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. The full file includes the same analysis, formatting, and structure shown here. No demo content or placeholders—just the finished report, ready to use.
Dogs
REGEN-COV 0 active commercial use
REGEN-COV has no active commercial use for Regeneron Pharmaceuticals, Inc.; FDA authorization was effectively ended as Omicron-era variants made it ineffective. With no current COVID demand and no clear turnaround path, it generates no meaningful sales and fits the Dogs quadrant.
ZALTRAP metastatic colorectal cancer low uptake
ZALTRAP (ziv-aflibercept) remains a niche mCRC drug in a crowded oncology field dominated by bevacizumab and newer regimens. Regeneron does not disclose material ZALTRAP revenue in recent filings, which points to very low uptake and little growth. With weak share and limited strategic value, ZALTRAP fits the Dog bucket.
Praluent PCSK9 share below Repatha
Praluent sits in a mature PCSK9 market that is led by Repatha, which posted about $2.0 billion in 2024 sales. Praluent has stayed well behind for years, with limited growth and much smaller economic value. That weak share, in a slow-growing category, fits Dog territory in the BCG matrix.
Kevzara rheumatoid arthritis mature competition
Kevzara sits in a crowded, mature RA market with entrenched TNF and JAK rivals, so it has not become a dominant brand. Regeneron Pharmaceuticals, Inc. reported $14.2 billion in 2024 revenue, while Kevzara remained a small contributor versus newer assets like Dupixent, which keeps it in the Dog box.
- RA market is mature and crowded
- Kevzara lacks category leadership
- Sales are small versus Regeneron core assets
- Low growth, low share = Dog
Inmazeb Zaire ebolavirus outbreak driven demand
Inmazeb is tied to rare, outbreak-based Zaire ebolavirus demand, so sales are episodic rather than recurring. Regeneron Pharmaceuticals, Inc. gets no broad scale from it; the market only opens during Ebola flareups, which are infrequent and often localized. That makes Inmazeb a clear Dog in the BCG Matrix: low growth, limited volume, and weak long-term scale potential.
- Rare, outbreak-driven demand
- No steady commercial run-rate
- Limited scale and revenue ceiling
- BCG fit: Dog
Regeneron’s “Dog” products stay small, weak-growth, and non-core
Regeneron Pharmaceuticals, Inc. Dogs are legacy or niche products with weak growth and low share. REGEN-COV, ZALTRAP, Praluent, Kevzara, and Inmazeb add little to 2025/2026 sales and face shrinking or episodic demand.
With Regeneron Pharmaceuticals, Inc. 2025 revenue still driven by Dupixent and EYLEA, these brands remain small and non-core. Low growth plus low market share keeps them in the Dog quadrant.
| Product | 2025/2026 signal | BCG |
|---|---|---|
| REGEN-COV | No active commercial use | Dog |
| ZALTRAP | Minimal disclosed sales | Dog |
| Praluent | Weak PCSK9 share | Dog |
| Kevzara | Small in crowded RA | Dog |
| Inmazeb | Outbreak-driven demand | Dog |
Question Marks
Eylea HD 8 mg launched 2023
Eylea HD 8 mg, launched in 2023, targets the same wet AMD, DME, and RVO market as Eylea but with dosing up to every 16 weeks after the loading phase. Uptake is rising, but Regeneron Pharmaceuticals, Inc. now faces sharper competition and aflibercept biosimilars, so share is still being built. That makes it a Question Mark in the BCG Matrix.
Libtayo PD-1 oncology franchise
Libtayo sits in a huge PD-1 market led by Merck’s Keytruda and BMS’s Opdivo; Keytruda alone posted about $29.5B in 2024 sales. Regeneron Pharmaceuticals, Inc. has approved uses in CSCC, NSCLC, and cervical cancer, but Libtayo’s scale is still far smaller, with 2024 net product sales near $1.3B. Growth is possible, yet the franchise is not secure against the category leaders, so it fits a Question Mark in the BCG Matrix.
Linvoseltamab BCMAxCD3 late-stage myeloma
Multiple myeloma is a growing hematology market, with roughly 36,000 new U.S. cases a year and a global market already in the tens of billions. Linvoseltamab is still a developing BCMAxCD3 asset, so its market share is unproven today. If clinical and regulatory momentum holds, it could scale fast; for now, it fits Regeneron Pharmaceuticals, Inc. as a Question Mark.
Itepekimab IL-33 COPD and asthma
Itepekimab, Regeneron Pharmaceuticals, Inc.’s IL-33 antibody, sits in a huge but still open market: COPD affects about 390 million people and asthma about 262 million worldwide. It has no commercial share yet because it is still in development, so the near-term revenue is zero. That mix of big upside and high trial risk fits a Question Mark.
Large need, no sales yet.
High upside, but approval is uncertain.
Fianlimab LAG-3 immuno-oncology
Fianlimab sits in a Question Mark spot in Regeneron Pharmaceuticals, Inc.'s BCG Matrix: LAG-3 is a real growth area, but Regeneron has 0% commercial share today because fianlimab is still not approved. The upside is meaningful, since the LAG-3 class already reached market with 1 approved combo therapy, but fianlimab still needs strong late-stage data and regulatory wins.
It can become a star asset, but for now it is a high-risk, high-reward bet.
- Market share today: 0%
- Not yet a commercial product
- LAG-3 has 1 approved therapy classwide
- Needs data, approval, and launch
Regeneron’s High-Upside, Low-Share Pipeline
Eylea HD, Libtayo, and linvoseltamab are Regeneron Pharmaceuticals, Inc. Question Marks: each has a big market, but share is still being built. Libtayo reached about $1.3B in 2024 sales, while Keytruda was about $29.5B, showing the gap. Itepekimab and fianlimab still have no commercial sales, so upside is high but risk is too.
| Asset | Signal | 2024/25 |
|---|---|---|
| Libtayo | Low share | $1.3B |
| Keytruda | Market leader | $29.5B |
| Fianlimab | No sales | 0% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.